Market Cap 114.41M
Revenue (ttm) 74.89M
Net Income (ttm) -43.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -57.68%
Debt to Equity Ratio 4.90
Volume 1,387,800
Avg Vol 1,632,890
Day's Range N/A - N/A
Shares Out 30.35M
Stochastic %K 13%
Beta 2.07
Analysts Strong Sell
Price Target $6.83

Latest News on STIM

Neuronetics, Inc. (STIM) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 9:52 AM EST - 27 days ago

Neuronetics, Inc. (STIM) Q4 2024 Earnings Call Transcript


Neuronetics and Greenbrook TMS Announce Closing of Transaction

Dec 10, 2024, 10:00 AM EST - 3 months ago

Neuronetics and Greenbrook TMS Announce Closing of Transaction


Neuronetics, Inc. (STIM) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 8:41 PM EST - 4 months ago

Neuronetics, Inc. (STIM) Q3 2024 Earnings Call Transcript


NeuroStar® Releases Software Upgrades to Elevate Patient Care

Sep 16, 2024, 8:32 AM EDT - 7 months ago

NeuroStar® Releases Software Upgrades to Elevate Patient Care


Neuronetics, Inc. (STIM) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 1:59 PM EDT - 8 months ago

Neuronetics, Inc. (STIM) Q2 2024 Earnings Call Transcript


NeuroStar® Launches Better Me Provider Program Nationwide

Jul 1, 2024, 8:02 AM EDT - 9 months ago

NeuroStar® Launches Better Me Provider Program Nationwide


Neuronetics, Inc. (STIM) Q1 2024 Earnings Call Transcript

May 7, 2024, 5:16 PM EDT - 11 months ago

Neuronetics, Inc. (STIM) Q1 2024 Earnings Call Transcript


Neuronetics, Inc. (STIM) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 12:19 PM EST - 1 year ago

Neuronetics, Inc. (STIM) Q4 2023 Earnings Call Transcript


NeuroStar TMS Receives Expanded Regulatory Approval in Japan

Dec 4, 2023, 8:56 AM EST - 1 year ago

NeuroStar TMS Receives Expanded Regulatory Approval in Japan